Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
77.62
-0.56 (-0.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
47
48
Next >
AstraZeneca's COVID-19 Therapy Approved In Britain As Preventive Option
March 17, 2022
Britain's Medicines and Healthcare products Regulatory Agency (MHRA)
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
March 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody
March 16, 2022
Via
Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
March 16, 2022
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren&
Via
Benzinga
White House Warns It Cannot Afford COVID-19 Related Solutions If Cases Increase: FT
March 16, 2022
The White House says that the U.S. is running out of money to pay for COVID-19 vaccines, tests, and treatments, making it unprepared for any rising cases in the future.
Via
Benzinga
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients
March 15, 2022
Merck & Co Inc (NYSE: MRK) will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Hopes For A Peace Accord
March 14, 2022
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.
Via
Talk Markets
FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition
March 14, 2022
The FDA has declined to approve AstraZeneca Plc's (NASDAQ: AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a...
Via
Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
March 14, 2022
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-...
Via
Benzinga
Upcoming Stock Splits 2022: 20 Companies That Could Follow Amazon’s Lead
March 10, 2022
We're taking a gander at more companies that could follow Amazon's (AMZN) lead with potential upcoming stock splits in 2022.
Via
InvestorPlace
How A Mixed Breast Cancer Study Cast Doubt On Gilead's Immunomedics Buyout
March 07, 2022
Gilead's Trodelvy had mixed test results in patients with breast cancer.
Via
Investor's Business Daily
Merck (MRK) Outperforms Industry, What's In Store For 2022?
March 07, 2022
Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.
Via
Talk Markets
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
March 03, 2022
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory...
Via
Benzinga
AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants
February 25, 2022
The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab)....
Via
Benzinga
Stock Market Tumbles, Rebounds As Russia Invades Ukraine: Weekly Review
February 25, 2022
The stock market fell back into a correction, but is trying to rally back.
Via
Investor's Business Daily
Red Ink
February 24, 2022
There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph
Via
Talk Markets
4 Pharma Stocks to Buy Even if the Pandemic Ends
February 24, 2022
Here are four pharma stocks that looks attractive for the long-term. Deep product development pipelines will ensure steady revenue and cash flow growth.
Via
InvestorPlace
Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study Shows
February 23, 2022
A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found between one and three cases per million, and only after...
Via
Benzinga
7 Safe Stocks to Buy If You Fear the Bear
February 23, 2022
Safe stocks tend to perform well no matter what the broader market does. Here are seven defensive companies to research further.
Via
InvestorPlace
AstraZeneca Gaps Higher After Touting 'Historic' And Unexpected Win In Breast Cancer
February 22, 2022
The company is testing a HER2 drug. It showed unexpected promise in some patients.
Via
Investor's Business Daily
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
February 22, 2022
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...
Via
Benzinga
AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
February 22, 2022
AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2...
Via
Benzinga
70 Firms Going Ex-Dividend Next Week, Including GlaxoSmithKline, Dow And AstraZeneca
February 19, 2022
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend.
Via
Talk Markets
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
February 18, 2022
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety...
Via
Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
Short Shelf Life Of AstraZeneca's COVID-19 Shot Entangles Vaccine Rollout In Poorer Nations: Reuters
February 16, 2022
According to officials and internal World Health Organization documents reviewed by Reuters, the relatively short shelf life of AstraZeneca Plc's (NASDAQ: AZN)...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data, Fed Minutes
February 16, 2022
Pre-open movers
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.